FDA approves first PSMA PET imaging agent for prostate cancer

Jul 12, 2021 Radiology Updates

US FDA approves the Piflufolastat F-18 injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage.

This is a highly effective imaging approach to detect the spread of cancer to other parts of the body.

Read the full article: 


Leave a Reply

Your email address will not be published. Required fields are marked *